Market Place
Sourcing Support
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
09 May 2024 //
GLOBENEWSWIRE
Eton Announces Commercial Availability of Nitisinone Capsules
02 Feb 2024 //
GLOBENEWSWIRE
Torrent`s Generic Nitisinone Receives Approval in the U.S.
09 Jan 2023 //
FDA
Sobi’s Orfadin Receives Positive Opinion From CHMP For Treatment Of AKU
20 Sep 2020 //
PHARMABIZ
Orfadin® (nitisinone) receives positive opinion from CHMP for treatment of AKU
18 Sep 2020 //
BIOSPACE
FDA Approvals Roundup: Detectnet, Nityr, Trelegy Ellipta
16 Sep 2020 //
RAPS
US FDA Grants Once Daily Dosing Option for NITYR Tablets for HT-1 Patients
14 Sep 2020 //
BUSINESSWIRE
Cycle Pharmaceuticals Secures $25 Million Debt Financing
06 Sep 2020 //
BUSINESSWIRE
Novitium Pharma`s Generic Nitisinone Receives Approval in US
27 Aug 2019 //
FDA
Celgene Europe BV Generic Azacitidine Receives Approval in Europe
08 Aug 2019 //
EMA
Copycats wanted: Pfizer, AZ and more under threat as China solicits generics
21 Jun 2019 //
FIERCE PHARMA
Cycle Pharmaceuticals` Nityr (nitisinone) Receives Approval in Europe
10 Aug 2018 //
EMA
MendeliKABS Europe`s Nitisinone MDK Receives Approval In Europe
06 Oct 2017 //
EMA
Swedish Orphan Biovitrum AB - Orfadin Capsules Approved in the Kingdom of Saudi Arabia
16 May 2017 //
PR NEWSWIRE
Dipharma announces the validation of disanit® (nitisinone) marketing authorization application in Europe
23 Feb 2017 //
PRESS RELEASE
WEP Clinical & MendeliKABS enter exclusive Named Patient distribution agreement
20 Feb 2017 //
SATPRNEWS
Sobi receives European approval for new dosing frequency for Orfadin
06 Feb 2017 //
PHARMABIZ
Sobi Obtains Approval From the European Commission for new Dosing Frequency
02 Feb 2017 //
FINANCE YAHOO
Sobi Receives Health Canada Approval for Orfadin Capsules
07 Jan 2017 //
PHARMABIZ
Health Canada greenlights MendeliKABS for the commercialization
11 Oct 2016 //
NEWSWIRE
Drug that cures rare disease hereditary tyrosinaemia type 1 gets approval
09 Jul 2016 //
NEWS
FDA approves Sobi`s Orfadin 20 mg caps. to treat hereditary tyrosinaemia type-1
17 Jun 2016 //
PHARMABIZ
FDA approves higher dosage strength Orfadin capsule for HT-1 treatment
15 Jun 2016 //
PBR
Canada confirms its first sexually transmitted Zika case
25 Apr 2016 //
REUTERS
Sobi`s Orfadin oral suspension gets EU patent to treat hereditary tyrosinaemia
20 Jan 2016 //
PHARMABIZ
Orphan drug firm Sobi opens new European base
11 Sep 2015 //
PM LIVE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.